Novel gene therapy for drug-resistant melanoma: Synergistic combination of PTEN plasmid and BRD4 PROTAC-loaded lipid nanocarriers

• Auteurs principaux: Aishwarya Saraswat (Auteur), Hari Priya Vemana (Auteur), Vikas Dukhande (Auteur), Ketan Patel (Auteur)
• Format: Livre
• Publié: Elsevier, 2024-09-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Patients suffering from BRAF mutant melanoma have tumor recurrence within merely 7 months of treatment with a potent BRAF inhibitor (BRAFi) like vemurafenib. It has been proven that diverse molecular pathways driving BRAFi resistance converge to activation of c-Myc in melanoma. Therefore, we identif...